NETRIS Pharma
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
28 Rue Laennec, Lyon, Auvergne-Rhone-Alp...Phone Number
+33 478782953Website
www.netrispharma.comRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About NETRIS Pharma
NETRIS Pharma is a clinical-stage immuno-oncology company that operates within a comprehensive cancer center in Lyon, France. The company focuses on developing first-in-class therapeutics targeting Netrin-1 to overcome resistance in oncology treatments. With a unique portfolio of intellectual property rights, NETRIS Pharma aims to provide innovative solutions for patients facing challenges with chemotherapy, targeted therapy, and immunotherapy. Their strategic partnerships enhance their research and clinical capabilities, positioning them as a leader in the biopharmaceutical field.Explore more
NETRIS Pharma Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NETRIS Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if NETRIS Pharma is spiking on competitors!
Funding: Get notified immidiatlly once NETRIS Pharma has new funding data
NETRIS Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when NETRIS Pharma launches new products
Click to see if NETRIS Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at NETRIS Pharma
Earning: See what the market has to say on NETRIS Pharma recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if NETRIS Pharma has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
NETRIS Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NETRIS Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NETRIS Pharma.
NETRIS Pharma financials insights
Gather financial insights about NETRIS Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Unspecified
$8.4M
NETRIS Pharma Tech Stack
A closer look at the technologies used by NETRIS Pharma
Most Recent Scoops
Funding
Funding
New Hire
Executive Move
Executive Moves, New Hire
Event
will be attending the 2022 BIO International Convention conference as an exhibitor. The event will occur from June 13 to June 16, 2022.
Event
NETRIS Pharma News & Media
NETRIS Pharma: Nature publishes positive pancreatic cancer Phase 1b data for NP137 anti-netrin-1 monoclonal antibody
Positive results from “LAPNET-01,” phase 1b trial of NP137 in patients with pancreatic ductal adenocarcinoma, published in Nature.NETRIS Pharma to Present Clinical Results of NP137 in Combination with Immune Checkpoint Inhibitors at ESMO 2025
Primary efficacy endpoint met in secondary refractory patients LYON, FRANCE, October 19, 2025 /EINPresswire.com/ -- NETRIS Pharma, a clinical-stage biotechnology company pioneering novel therapies targeting Netrin-1 to overcome resistance to …NETRIS Pharma appoints Dr. Sébastien Hazard as Chief Medical Officer to Lead Next Phase of Clinical Development
NETRIS Pharma is advancing its pipeline into later-stage clinical trials LYON, FRANCE, September 18, 2025 /EINPresswire.com/ -- NETRIS Pharma, a clinical-stage biotechnology company developing first-in-class therapeutics targeting Netrin-1 and its role …NETRIS Pharma Announces Positive Interim Phase II Results for NP137 in combination with anti-PD(L)1
Confirmation of NP137 Potential to Overcome Resistance to Immune Checkpoint - Clinical Trial Design and Interim Results to be Presented at ASCO and ESMO 2025 LYON, FRANCE, April 25, 2025 /EINPresswire.com/ -- NETRIS Pharma, a clinical-stage private …
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NETRIS Pharma
Sign Up For FreeTo access detailed company insights
NETRIS Pharma is a clinical-stage immuno-oncology company that operates within a comprehensive cancer center in Lyon, France. The company focuses on developing first-in-class therapeutics targeting Netrin-1 to overcome resistance in oncology treatments. With a unique portfolio of intellectual property rights, NETRIS Pharma aims to provide innovativ... Read More
